OLIGONUCLEOTIDE SYNTHESIS MARKET ANALYSIS

Market Challenges And Opportunities

Global Oligonucleotide Synthesis Market– Drivers

• Increasing Collaboration Agreements by the Market Players: Market players are engaged in inorganic growth strategies such as collaborations in order to provide data interpretation software to universities conducting research and development activities. This is expected to drive the growth of the global oligonucleotide synthesis market over the forecast period. For instance, in June 2021, Thermo Fisher Scientific, U.S. supplier of analytical instruments, life sciences solutions, specialty diagnostics, laboratory, pharmaceutical and biotechnology services announced a collaboration with the University of Sheffield to develop advanced end-to-end workflows for the characterization and monitoring of complex oligonucleotide and mRNA products. This collaboration provided data interpretation software technologies to the University of Sheffield for the development of streamlined analytical workflows and robust fit-for-purpose processes.
• Increasing Acquisition by the Market Players: Market players are focused on inorganic growth strategies, such as signing acquisition agreements, in order to expand its product portfolio and geographical presence in the market. In January 2022, Merck KGaA, German multinational science and technology company,  announced a definitive agreement to acquire Exelead, a biopharmaceutical contract development and manufacturing organization (CDMO). Exelead specializes in complex injectable formulations, including lipid nanoparticle (LNP), as well as other products such as liposomal complexes and oligonucleotides. 

Global Oligonucleotide Synthesis Market: Key Trends

• Introduction of oligonucleotide synthesis with advanced technology: Market players are engaged in inorganic activities such as collaboration for the innovation of new oligonucleotide equipment. This is expected to increase the growth of the global oligonucleotide synthesis market, over the forecast period For instance, On December 18, PeptiSystems,  a company that offers a new generation of instruments for solid-phase synthesis production of peptide and oligonucleotide therapeutics, and CordenPharma, a full-service contract development and manufacturing organization (CDMO), entered into a collaboration agreement for testing and evaluation of a new generation of peptide synthesis technology. Under the terms of this agreement, CordenPharma will evaluate a new synthesis instrument, PeptiPilot, developed by PeptiSystems. It is based on flow through column technology. This technology can be used for process development and large-scale commercial manufacturing of peptides of non-GMP and GMP quality.

Global Oligonucleotide Synthesis Market: Restraint

• Low Quality and Complexity of Oligonucleotide Products: Natural oligonucleotides are composed of ribose or deoxyribose sugar phosphate as a base, which are quickly degraded in the body by nucleus. Moreover, in generic testing, Oligo degradation can affect cell growth and proliferation. Furthermore, the low quality of microarray-generated oligonucleotide sequences is a major challenge in adopting microarray technology for oligonucleotide synthesis. These factors are expected to restrain the global oligonucleotide synthesis market growth. For instance, oligonucleotides act on the RNA level through different molecular pathways, but there is a major drawback when using them as drugs: their poor bioavailability and cellular uptake. These considerations limit their application as therapeutics. To address these problems, it is vital to develop delivery systems that enable oligonucleotides to reach their targets: cell-penetrating peptides (CPPs) present a potential solution to this issue. To overcome the challenge, on March 10 , 2022, Bachem, a company specializing in the development and manufacturing of peptides and oligonucleotides, developed cell-penetrating peptides (CPPs) as a delivery system for oligonucleotides.